Trevena Stock Is a ‘Buy’ Ahead of Olinvyk Launch, Says Analyst

Despite the recent pullback, Trevena (TRVN) stock has had an excellent 2020 with shares rocketing 182% year-to-date. According to H.C. Wainwright analyst Douglas Tsao, there’s a lot of fuel left in the tank.Tsao’s confidence is based on the imminent launch of Olinvyk, the company’s recently approved opioid agonist for the treatment of moderate to severe acute pain in adults. Olinvyk has been designated Schedule 2 status by the DEA and will hit the market this month.Trevena has just revealed its price plan for the drug; Olinvyk will be sold in three sizes: 1 and 2mg vials for bolus dosing costing …read more

Source:: Yahoo Finance


Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.